Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2010

View Archived Issues

Albert Einstein College of Medicine claims hypoxia-targeted agents

Effect of citalopram on drinking depends on goals of alcohol-dependent subjects

RespiVert claims MAPK p38 inhibitors

AstraZeneca discovers new inhibitors of DAT and NET

Histamine H3 receptor ligands claimed by Merck & Co.

Merck & Co. claims new glucagon receptor antagonists

Nerviano describes new B-raf kinase inhibitors

BHT-3021 shows promise in phase I/II trial in type 1 diabetes

Weekly rituximab reduces proteinuria in idiopathic membranous nephropathy

Exelixis presents preclinical data on agents investigated for diabetes

Viamet describes new cytochrome P450-C17 inhibitors

Western States Biopharma and University of Colorado to develop TCISM-targeting agents

Selvita and Orion collaborate on SEL-103 program in AD

KAEL-GemVax reports phase III data on tertomotide in pancreatic cancer

Imiquimod superior to placebo in phase III program for external genital warts

Results reported from phase II study of gemcitabine/Amplimexon in pancreatic cancer

Midatech and Immunotope join to form Syntara to develop immune therapies

Adimab and Novartis partner after launch of antibody discovery platform

Interim phase IIb data reported on TMC-435 in HCV infection

FDA accepts Protalix's NDA for taliglucerase alfa

Hemispherx reports on Japanese trials of nasal H5N1 vaccine

JDRF awards Biodel grants for its VIAject diabetes therapy

Mesoblast and FDA to discuss phase III program for bone marrow regeneration

Quest PharmaTech forms clinical advisory panel for oregovomab

Clinuvel reports on phase III trial of Scenesse in EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...